Trials / Completed
CompletedNCT00320411
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
Phase II Clinical Study of Lapatinib (GW572016) in Patients With ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This study (EGF104911) is designed to evaluate the efficacy and safety of lapatinib in patients with advanced or metastatic breast cancer. Eligible subjects must have ErbB2 overexpressing tumors and are refractory to treatment with anthracycline, taxanes and trastuzumab containing regimens. The study data obtained from EGF104911 will be combined with the data from EGF100642 and integrated analysis will be carried out in order to enhance the credibility of the study results.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib | Lapatinib 1500mg QD |
Timeline
- Start date
- 2005-11-28
- Primary completion
- 2009-04-01
- Completion
- 2009-04-01
- First posted
- 2006-05-03
- Last updated
- 2019-01-31
- Results posted
- 2009-12-14
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00320411. Inclusion in this directory is not an endorsement.